HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced today the commencement of an underwritten public offering of shares of its common stock or common stock equivalents. The final size and terms of the offering are subject to market conditions, with all securities to be offered by the company. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the offering.
The company intends to use the net proceeds from the offering to advance the commercialization of its FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection initiatives, enhance its artificial intelligence capabilities, and support working capital and general corporate purposes. This strategic move underscores HeartBeam's commitment to expanding its footprint in the cardiac care market and leveraging AI to improve diagnostic accuracy.
HeartBeam's platform technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, all without a cable. The system received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology.
The offering comes at a pivotal time as HeartBeam seeks to capitalize on its recent regulatory milestones and bring its innovative solutions to a broader patient population. The company's technology aims to enable physicians to identify cardiac health trends and acute conditions outside of medical facilities, potentially transforming cardiac health management. For more details on the offering, the full press release is available at https://ibn.fm/pxFOz.
HeartBeam's focus on AI integration is particularly noteworthy, as artificial intelligence can enhance the analysis of ECG data, leading to earlier detection of heart attacks and other cardiac events. The extended-wear patch initiative also promises to provide continuous monitoring, which could be crucial for patients with intermittent symptoms.
Investors and industry observers will be watching the offering closely, as the proceeds will directly support HeartBeam's commercial rollout and technological advancements. The company's latest news and updates are available in its newsroom at https://ibn.fm/BEAT. For cleared indications for use of its technology, refer to https://www.heartbeam.com/indications.
This announcement highlights the growing importance of portable, AI-enhanced diagnostic tools in cardiology. By securing additional funding, HeartBeam is positioning itself to compete in the rapidly evolving digital health landscape.
